VK2735 – Talk Bio

Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate

1 month ago talkbio0Tagged CordenPharma, GLP-1/GIP, Manufacturing, Obesity, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, obesity drug, manufacturing agreement, GLP-1/GIP dual agonist

Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735

1 month ago talkbio0Tagged alpha 1-antitrypsin, Capacity, Contract agreement, CordenPharma, Fill/finish, GLP-1/GIP Dual Agonist, Obesity, oral formulations, production, subcutaneous, Viking, VK2735

Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations

Viking Therapeutics’ Oral Weight Loss Drug VK2735 Shows Promising Phase 1 Results

6 months ago talkbio0Tagged GLP-1/GIP Dual Agonist, Obesity, oral weight loss drug, phase 1 trial, VK2735

VK2735, Viking Therapeutics, oral weight loss drug, GLP-1/GIP dual agonist, obesity treatment, Phase 1 trial results

Viking Therapeutics Accelerates Obesity Drug Development to Phase 3 Trials

9 months ago talkbio0Tagged competition, GLP-1/GIP receptor agonist, Market, Obesity, Phase 3 trials, Viking, VK2735, Weight Loss

Viking Therapeutics, Obesity Drug, Phase 3 Trials, GLP-1/GIP Receptor Agonist, VK2735, Weight Loss, Market Competition